WHO Position Paper on Measles Vaccines, Aug 2009

References

Epidemiology


Measles viruses


Measles disease


Measles vaccines


WHO/UNICEF measles vaccination coverage information: http://www.who.int/vaccines-surveillance/graphics/htmls/IncMeas.htm

Immunogenicity


Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and
a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 2009 Apr 14;7:16.


Efficacy-Effectiveness


Duration of protection/persistence of antibodies


One versus two doses


HIV and measles vaccination


Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 2003 Jun;111(6 Pt 1):e641-4.


Safety


Last update: 12 April 2006


Barlow WE, Davis RL, Glasser JW. The risk of seizures after receipt of whole cell pertussis or measles mumps and rubella vaccine. N Engl J Med 2001;345:656-661.

Carapetis JR, Curtis N. MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare. BMJ. 2001 October 13; 323(7317): 869.


Cost-effectiveness


Policy issues


